IMMUNOMODULATORY THERAPIES FOR PREVENTING THROMBOSIS IN IMMUNE-MEDIATED MICROVASCULAR THROMBOTIC DISEASES

Immune-mediated microvascular thrombotic diseases (IMTD), such as systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS), increase the risk of microvascular thrombosis due to chronic inflammation and autoimmune activity. While anticoagulant therapy is crucial for managing thrombotic events, immunomodulatory therapies may provide additional benefits by targeting underlying immune dysfunction. This study evaluated the efficacy of biologic agents (IL-6 antagonists, TNF inhibitors, rituximab) and complement inhibitors in reducing thrombotic risk over 12 months in 50 patients with IMTD (aged 18–65). Inflammatory markers (CRP, IL-6) and thrombotic indicators (D-dimer, fibrinogen) were elevated at baseline and significantly decreased post-therapy (p<0.01). Rituximab reduced antibody levels by 30% in SLE patients (p<0.05), with a 15% reduction in thrombotic events. IL-6 antagonists decreased inflammation and thrombotic risk by 20% (p=0.03). However, bleeding risk was observed in 8% of patients. These findings highlight the potential of immunomodulatory therapies as adjuncts to anticoagulants, though larger trials are needed.